Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 22, 2015
Grant Date -
Nov 10, 2011
app pub date -
Mar 14, 2011
filing date -
Mar 14, 2010
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully